Neogenomics Inc: (NASD: NEO)

$3.54

-0.13 (-3.54%)

Volume 91,234

May 21 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		3.53 - 3.79
	
		52wk Low - High
		1.55 - 4.20
	
		Previous Close
		3.67
	
		Avg. Volume
		125,924
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		176.64 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.98
	
		PE (Forward)
		104.86
	
		Current Year Est.
		0.04
	
		Quarterly Earnings ESP 
		-100.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
NA

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		NA
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of NA

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            104.86
                        
                            PEG Ratio
                            5.24
                        
                            Current Year Est.
                            0.04
                        
                            Current Quarter Estimate
                            0.01
                        
                            Most Accurate Estimate
                            0.00
                        
                            Earnings ESP 
                            -100.00%
                        
                            Next Earnings Report Date
                            07-18-2013
                        
                            EPS Last Year
                            -0.01
                        
                            Expected Earnings Growth
                            20.00%
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization, flow cytometry, morphology studies, anatomic pathology and molecular genetic testing. Headquartered in Fort Myers, FL, NeoGenomics has labs in Nashville, TN, Irvine, CA and Fort Myers and services the needs of pathologists, oncologists, urologists, hospitals and other reference laboratories throughout the United States.   
Full NEO Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
NEO Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	0.01	0.01	0.04	0.14
Number of Estimates	3	3	4	2
Low Estimate	0.00	0.01	0.03	0.12
High Estimate	0.01	0.01	0.04	NA
Year Ago EPS	0.01	-0.02	0.00	0.04
EPS Growth	-33.33%	150.00%	NA	285.71%

More NEO Estimates

Average Earnings Estimates for NEO

EPS Growth for NEO

Industry Analysis

Name	Symbol	Previous Close
NEOGENOMICS INC	NEO	3.67
AETERNA ZENTARS	AEZS	2.06
ANIKA THERAPEUT	ANIK	14.39
GENTIUM SPA-ADR	GENT	8.84
AASTROM BIOSCI	ASTM	0.59
ACHILLION PHARM	ACHN	7.55
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.27
ALEXION PHARMA	ALXN	100.03
ALKERMES INC	ALKS	31.04

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

NeoGenomics: What Can We Expect for 2013

Feb 28, 2013

NeoGenomics Is Poised to Grow in 2013

Dec 28, 2012

NeoGenomics is Poised to Grow further in 2013

Dec 18, 2012

Report Not Available

More NEO Zacks Commentary

Financials

EPS TTM	-0.01
Sales	60
Net Income	-1
Price/Earnings	NA
Price/Book	18.04
Price/Cash Flow	42.44
Price/Sales	2.93

More NEO Financials

News

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 14, 2013

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

May 13, 2013

NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter - Pr Newswire

Apr 25, 2013

NeoGenomics Sees Revenue Below Estimates - Earningswhispers Earnings Guidance

Apr 25, 2013

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

Apr 18, 2013

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

Apr 17, 2013

NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013 - Pr Newswire

Apr 17, 2013

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

Apr 16, 2013

See All News Stories on NEO

Broker Recommendations

Current ABR	1.50
ABR (Last Week)	1.50
# of recs in ABR	4
Average Target Price	5.33
Industry Rank by ABR	91 out of 265
Rank in Industry	38 out of 156

More NEO Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member

Neogenomics Inc: (NASD: NEO)

$3.54

-0.13 (-3.54%)

Volume 91,234

May 21 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-BIOMED/GENE

Zacks Commentary

NeoGenomics: What Can We Expect for 2013

NeoGenomics Is Poised to Grow in 2013

NeoGenomics is Poised to Grow further in 2013

Report Not Available

Financials

News

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

NeoGenomics Reports Record Quarterly Revenue of $15.7 Million, Adjusted EBITDA of $1.8 Million and 46.3% Gross Margin for the First Quarter - Pr Newswire

NeoGenomics Sees Revenue Below Estimates - Earningswhispers Earnings Guidance

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

NeoGenomics Schedules its Q1 2013 Earnings Release for April 25, 2013 - Pr Newswire

NeoGenomics Inc.Corporate Event Announcement Notice - Wall Street Horizon

Broker Recommendations

Day Low - High	3.53 - 3.79
52wk Low - High	1.55 - 4.20
Previous Close	3.67
Avg. Volume	125,924
Industry	MED-BIOMED/GENE
Market Cap	176.64 M
Div - Yield	0.00 - 0.00
Beta	0.98
PE (Forward)	104.86
Current Year Est.	0.04
Quarterly Earnings ESP	-100.00%

PE (Forward)	104.86
PEG Ratio	5.24
Current Year Est.	0.04
Current Quarter Estimate	0.01
Most Accurate Estimate	0.00
Earnings ESP	-100.00%
Next Earnings Report Date	07-18-2013
EPS Last Year	-0.01
Expected Earnings Growth	20.00%